Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:canBe |
treatment of rheumatoid arthritis
treatment of inflammatory diseases |
| gptkbp:CASNumber |
387867-13-2
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C22H19N5O2
|
| gptkbp:hasSMILES |
C1=CC(=CC(=C1)C2=CC=NN2)NC(=O)CN3C=NC(=NC3)C4=CC=NC=C4
|
| https://www.w3.org/2000/01/rdf-schema#label |
VX-702
|
| gptkbp:isKinaseInhibitor |
true
|
| gptkbp:IUPACName |
N-(3-(1H-pyrazol-3-yl)phenyl)-2-(4-pyridin-4-ylpyrimidin-2-ylamino)acetamide
|
| gptkbp:PubChem_CID |
CHEMBL1201832
9910476 |
| gptkbp:synonym |
N-(3-(1H-pyrazol-3-yl)phenyl)-2-(4-pyridin-4-ylpyrimidin-2-ylamino)acetamide
|
| gptkbp:target |
gptkb:p38_MAP_kinase
|
| gptkbp:bfsParent |
gptkb:MAPK/p38_pathway
gptkb:MAPK14 |
| gptkbp:bfsLayer |
7
|